Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2Other hematologic neoplasm 2

Conditions

Lymphoma 201Leukemia 159Leukemia, Myeloid, Acute 134Precursor Cell Lymphoblastic Leukemia-Lymphoma 132Lymphoma, Non-Hodgkin 112Multiple Myeloma 111Lymphoma, Large B-Cell, Diffuse 108Lymphoma, Follicular 93Hodgkin Disease 92Burkitt Lymphoma 91Myelodysplastic Syndromes 87Lymphoma, Mantle-Cell 87Breast Neoplasms 85Leukemia, Lymphocytic, Chronic, B-Cell 84Lymphoma, Large-Cell, Immunoblastic 73Lymphoma, B-Cell, Marginal Zone 59Sarcoma 54Neoplasms, Plasma Cell 50Neuroblastoma 49Central Nervous System Neoplasms 46Leukemia, Myeloid, Chronic-Phase 43Recurrence 40Ovarian Neoplasms 39Leukemia, Myeloid, Accelerated Phase 39Congenital Abnormalities 39Myeloproliferative Disorders 38Dendritic Cell Sarcoma, Interdigitating 38Blast Crisis 34Leukemia, Myelomonocytic, Chronic 32Neutropenia 29

Interventions

Dexamethasone 8Lenalidomide 4dexamethasone acetate 3dexamethasone 21-phosphate 3daratumumab 3auricularum 3Calcium Dobesilate 3Bortezomib 3pomalidomide 2ixazomib 2filanesib 2Steroids 2Radiotherapy 2Injections, Subcutaneous 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2silmitasertib 1navtemadlin; 2-((3R,5R,6S)-5-(3-chlorophenyl)-6-(4-chlorophenyl)-1-((S)-1-(isopropylsulfonyl)-3-methylbutan-2-yl)-3-methyl-2-oxopiperidin-3-yl)acetic acid 1milatuzumab 1cc-486 1carfilzomib 1Thalidomide 1Specimen Handling 1Sodium Selenite 1Radiation 1Proteasome Inhibitors 1Peripheral Blood Stem Cell Transplantation 1Panobinostat 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Plasmacytoma × Filgrastim × Clear all
NCT00821249 2020-10-19

A Study of ARRY-520 in Patients With Relapsed or Refractory Multiple Myeloma

Pfizer

Phase 1/2 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

NCT01248923 2020-09-30

A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

Array BioPharma

Phase 1 Completed
55 enrolled
Other hematologic neoplasmPlasma cell

Leukemia, Plasma Cell, Multiple Myeloma, Paraproteinemias, Plasmacytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡